片頭痛へのアプローチ

出版社： 先端医学社
著者：
発行日： 2004-01-20
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 4884071204
電子書籍版： 2004-01-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,170 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

＜働き盛りの世代の日常生活に支障を生じる片頭痛。よりよい日常生活を配慮した治療を目指すための一冊＞
新しい頭痛分類と診断基準が確立した昨今、治療面でも新薬が開発され、EBMに基づいた医療が行われるようになった。QOLを大きくそこなう頭痛に悩む患者は多いにもかかわらず受診率は多くない。本書では診療時の頭痛の基礎知識から患者指導に至るまで多岐にわたって紹介しており、頭痛治療に携わる医療従事者に必携の書。

目次

  • 片頭痛へのアプローチ

    ―目次―

    よりよい日常生活を配慮した診療を目指して

    Part1 頭痛診療の基礎知識
    　片頭痛のu学
    　片頭痛患者が受診する目的は何か
    　片頭痛と生活環境に及ぼす影響
    　片頭痛治療の医師-患者関係 ほか

    Part2 片頭痛の生理と病態
    　片頭痛の概念と分類
    　片頭痛の発症メカニズム
    　片頭痛とセロトニンの役割

    Part3 片頭痛の診断のポイント
    　国際頭痛学会診断基準の日常診療への生かし方
    　頭痛の鑑別診断のための問診のポイント ほか

    Part4 片頭痛の治療戦略
    　片頭痛の治療戦略のポイントは何か
    　片頭痛の病態・重症度に応じた治療戦略の立て方 ほか

    Part5 片頭痛の治療の実際
    　片頭痛に適応される薬剤の種類・特徴とその適応 ほか

    Part6 片頭痛患者への生活指導と服薬指導
    　片頭痛の誘因を避けるための日常生活指導のポイント ほか

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 / 頭痛診療の基礎知識

P.29 掲載の参考文献
1) International Headache Society:Classification and diagnostic criteria for head-ache disorders, cranial neuralgias, and facial pain. Cephalalgia 8(Suppl 7):1-96, 1988
 
2) Rasmussen BK, Jensen R, Schroll M et al:Epidemiology of headache in a general population:a prevalence study. J Clin Epidemiol 44:1147-1157, 1991
 
3) Henry P, Michel P, Brochet B et al:A nationwide survey of migraine in France:prevalence and clinical features in adults. Cephalalgia 12:229-237, 1992
PubMed
4) Stewart WF, Lipton RB, Celentano DD et al:Prevalence of migraine headache in the United States. JAMA 267:64-69, 1992
PubMed
5) Honkasalo ML, Kaprio J, Heikkila K et al:A population-based survey of headache and migraine in 22,809 adults. Headache 33:403-412, 1993
 
6) Gobel H, Petersen-Braun M, Soyka D:The epidemiology of headache in Germany:a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. Cephalalgia 14:97-106, 1994
 
7) Rasmussen BK:Migraine and tension-type headache in a general population:precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 53:65-72, 1993
 
8) Edmeads J, Findlay H, Tugwell P et al:Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use:a Canadian population survey. Can J Neurol Sci 20:131-137, 1993
PubMed
9) Stewart WF, Shechter A, Lipton RB:Migraine heterogeneity:disability, pain intensity, and attack frequency and duration.Neurology 44(Suppl 4):S24-39, 1994
 
10) Stang P, Cady R, Batenhorst A et al:Workplace Productivity, A review of the impact of migraine and its treatment. Pharmacoeconomics 19:231-244, 2001
 
11) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997
PubMed
12) Rasmussen BK, Jensen R, Olesen J:Questionnaire versus clinical interview in the diagnosis of headache. Headache 31:290-295, 1991
PubMed
13) Stewart WF, Shechter A, Rasmussen BK:Migraine prevalence:a review of population-based studies. Neurology 44(Suppl 4):S17-23, 1994
 
14) Lipton RB, Silberstein SD, Stewart WF:An update on the epidemiology of migraine. Headache 34:319-328, 1994
PubMed
P.36 掲載の参考文献
1) Packard RC:What does the headache patient want? Headache 19:370-374, 1979
 
2) Lipton RB, Stewart WF:Acute migraine therapy:Do doctors understand what patients with migraine want from therapy? Headache 39(Suppl 2):S20-26, 1999
 
3) Pietrini U, De Luca M, Del Bene E:Endpoints to evaluate efficacy of sympto-matic drugs in migraine:what do patients want? Headache 42:948-949, 2002
 
4) MacGregor EA:The doctor and the migraine patient:improving compliance. Neurology 48(Suppl 3):S16-20, 1997
 
P.46 掲載の参考文献
1) Lipton RB, Stewart WF, Diamond S et al:Prevalence and burden of migraine in the United States:data from the American Migraine Study II. Headache 41:646-657, 2001
PubMed
2) Solomon GD, Santanello N:Impact of migraine and migraine therapy on pro-ductivity and quality of life. Neurology 55(Suppl 2):S29-35, 2000
 
3) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997
PubMed
4) Lipton RB, Newman LC:Epidemiology, impact, and comorbidities of migraine headaches in the United States. Neurology 60(Suppl 2):S3-8, 2003
 
5) Lipton RB, Stewart WF, von Korff M:Burden of migraine:societal costs and therapeutic opportunities. Neurology 48(Suppl 3):S4-9, 1997
 
6) Bigal ME, Bigal JM, Betti M et al:Evaluation of the impact of migraine and episodic tension-type headache on the quality of life and performance of a uni-versity student population. Headache 41:710-719, 2001
 
7) Edmeads J, Mackell JA:The economic impact of migraine:an analysis of direct and indirect costs. Headache 42:501-509, 2002
PubMed
8) Solomon GD, Gregg LA, Skobieranda FG:Does quality of life differ among headache diagnosis? Analysis using the Medical Outcomes Study instrument. Headache 34:143-147, 1994
 
9) Stewart AL, Greenfield S, Hays RD et al:Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 262:907-913, 1989
PubMed
10) Solomon GD, Skobieranda FG, Gregg LA:Quality of life and well-being of headache patients:measurement by the Medical Outcomes Study instru-ment. Headache 33:351-358, 1993
 
11) Hartmaier SL, Silberstein SD, Epstein RS et al:Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache 35:320-329, 1995
PubMed
12) Santanello NC, Silberstein SD, Epstein RS:Validation of new quality of life questionnaire for acute migraine headache. Headache 35:330-337, 1995
PubMed
13) Wagner TH, Patrick DK, Galer BS et al:A new instrument to assess the long-term quality of life effectsfrom migraine:development and psychomet-ric testing of MSQOL. Headache 36:484-492, 1996
 
14) Jhingram P, Osterhaus JT, Miller DW et al:Development and validation of the migraine-specific quality of life questionnaire. Headache 38:295-302, 1998
 
15) Stewart WF, Lipton RB, Dowson AJ et al:Development and testing of the migraine diasability assessment(MINDS)questionnaire to assess headache-related disability. Neurology 56(Suppl 1):S20-28, 2001
 
16) Davies GM, Santanello NC, Gerth WC et al:Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia 19:497-502, 1999
 
17) Langeveld JH, Koot HM, Loonen MC et al:A quality of life instrument for adolescents with chronic headache. Cephalalgia 16:283-196, 1996
 
18) Santanello NC, Harmaier SL, DeMuro-Mercon C:Development of an adoles-cent migraine questionnaire[Abstract]. Neurology 50(Suppl 4):A434, 1998
 
19) Jones A, Jones R:Migraine in industry. In:Migraine:Clinical therapeutic comceptual and research aspects, ed by Blau JN, Chapman and Hall, London, 1987, pp.105-111
 
P.55 掲載の参考文献
1) Ong LM, de Haes JC, Hoos AM et al:Doctor-patient communication:a review of the literature. Soc Sci Med 40:903-918, 1995
PubMed
2) 中川薫:患者アウトカムとの関連からみた医師患者間のコミュニケーションに関する文献的考察. 保健医療社会学論集 12:32-46, 2001
 
3) Roter DL, Hall JA, Katz NR:Relations between physicians' behaviors and analogue patients' satisfaction, recall, and impressions. Med Care 25:437-451, 1987
PubMed
4) Smith CK, Polis E, Hadac RR:Characteristics of the initial medical interview associated with patient satisfaction and understanding. J Fam Pract 12:283-288, 1981
PubMed
5) Street RL Jr:Information-giving in medical consultations:the influence of patients' communicative styles and personal characteristics. Soc Sci Med 32:541-548, 1991
PubMed
6) Waitzkin H:Doctor-patient communication. Clinical implications of social sci-entific research. JAMA 252:2441-2446, 1984
 
7) Lipton RB, Stewart WF, Simon D:Medical consultation for migraine:results from the American Migraine Study. Headache 38:87-96, 1998
PubMed
8) Becker WJ:Communication with the migraine patient. Can J Neurol Sci 29(Suppl 2):S1-2, 2002
 
9) Fitzpatrick RM, Hopkins A:Patients' satisfaction with communication in neu-rological outpatient clinics. J Psychosom Res 25:329-334, 1981
 
10) Edmeads J:Communication issues in migraine diagnosis. Can J Neurol Sci 29(Suppl 2):S8-10, 2002
 
11) 津田司:心温かな医師になるためのコミュニケーション技法. 滋賀医学 24:1-12, 2001
 
12) Sheftell FD:Communicating the right therapy for the right patient at the right time:acute therapy. Can J Neurol Sci 29(Suppl 2):S33-39, 2002
 
P.65 掲載の参考文献
1) 片頭痛HRQol調査研究グループ(研究代表者 坂井文彦):片頭痛患者に対する医療経済学的調査報告書, 2001
 
2) 清水文彦, 岩田誠, 西村周三:片頭痛におけるスマトリプタン錠の医療経済学的検討. 診療と新薬 38:9, 2001
 
3) Rapoport AM, Adelman JU:Cost of Migraine Management:A Pharma-coeconomic Overview. Am J Man Care 4:531-545, 1998
 
4) Coukell AJ, Lamb HM:Sumatriptan:A Pharmacoeconomics Review of its Use in Migraine. Pharmacoeconomics 11:473-490, 1997
PubMed
5) http://www.ccohta.ca/newweb/pubapp/pubsearch.asp(Meta-analysis and economic evaluation of sumatriptan for migraine. カナダ医療技術評価調整局1996年発行報告書)
 
6) Evans KW, Boan JA, Evans JL et al:Economic Evaluation of Oral Sumatriptan Compared with Oral Caffeine/Ergotamine for Migraine. Pharmacoeconomics 12:565-577, 1997
PubMed
7) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997
PubMed
8) 労働省政策調査部編:平成10年度版「賃金センサス」, (財)労働法令協会, 東京, 1998
 
9) Drummond MF et al:Methods for the Economic Evaluation of Health Care Programs, Second Edition, Oxford Medical Publication, 1997, pp.96-231
 
10) Pryse-Philligs W, Findlay H, Tugwell P et al:A Canadian population survey of the clinical epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci 19:333-339, 1992
 
11) Kaplan R, Anderson J:A general health model:Update and applications. Health Services Research 23:203-235, 1998
 
12) 上村隆元:日本語版HUIの開発, 臨床経済学研究会第27回学術集会・総会, 2001年4月23日開催
 
13) Ikeda S Ikegami N:on behalf of Japanese EuroQol Tariff Project Health status in Japan:Results from Japanese EuroQol study. 医療と社会 9:83-92, 1999
 

Part 2 / 片頭痛の生理と病態

P.79 掲載の参考文献
1) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997
PubMed
2) International Headache Society:Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 8(Suppl 7):1-96, 1988
 
3) Silberstein ST, Saper JR, Freitag FG:Migraine:Diagnosis and treatment. In:Wolff's Headache and Other Head Pain 6th ed, ed by Silberstein SD, Lipton RB, Dalessio, Oxford University Press, New York, 2001, pp.129-237
 
4) 柴田興一:視覚前兆の神経生理学. 神経進歩 46:377-389, 2002
 
5) Ad Hoc Committee on Classification of Headache:Classification of headache. JAMA 179:717-718, 1962
 
6) Olesen J, Larsen B, Lauritzen M:Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic nigraine. Ann Neurol 9:344-352, 1981
PubMed
7) 濱田潤一:II. 片頭痛. 1. 診断基準と診断の実際. 日内会誌 90:581-588, 2001
 
8) Ophoff RA, Terwindt GM, Vergouwe MN et al:Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca channel gene CACNL1A4. Cell 87:543-552, 1996
PubMed
P.89 掲載の参考文献
1) Lance JW, Lambert GA, Goadsby PJ et al:5-Hydroxytryptamine and its puta-tive aetiological involvement in migraine. Cephalalgia 9(Suppl 9):7-13, 1989
 
2) Sicuteri F, Testi A, Anselmi B:Biochemical investigations in headache:increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 19:55-58, 1961
 
3) Anthony M:Plasma free fatty acid changes in migraine. Proc Aust Assoc Neu-rol 10:87-89, 1973
 
4) Takeshima T, Shimomura T, Takahashi K:Platelet activation in muscle contraction headache and migraine. Cephalalgia 7:239-243, 1987
PubMed
5) Hanington E, Jones RJ, Amess JA et al:Migraine:a platelet disorder. Lancet 2:720-723, 1981
 
6) Takeshima T, Takao Y, Urakami K et al:Muscle contraction headache and migraine. Platelet activation and plasma norepinephrine during the cold pressor test. Cephalalgia 9:7-13, 1989
PubMed
7) Ferrari MD, Saxena PR:On serotonin and migraine:a clinical and pharmacological review. Cephalalgia 13:151-165, 1993
 
8) Olesen J, Larsen B, Lauritzen M:Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 9:344-352, 1981
PubMed
9) Moskowitz MA, Macfarlane R:Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 5:159-177, 1993
PubMed
10) Ophoff RA, Terwindt GM, Vergouwe MN et al:Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543-552, 1996
PubMed
11) Ducros A, Denier C, Joutel A et al:The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med 345:17-24, 2001
 
12) Takeshima T, Fukuhara Y, Adachi Y et al:Leukocyte mitochondrial DNA A-to-G polymorphism at 11084 is not a risk factor for Japanese migraineurs. Cephalalgia 21:987-989, 2001
 
13) Reuter U, Bolay H, Jansen-Olesen I et al:Delayed inflammation in rat meninges:implications for migraine pathophysiology. Brain 124:2490-2502, 2001
PubMed
14) Russell MB, Iselius L, Olesen J:Migraine without aura and migraine with aura are inherited disorders. Cephalalgia 16:305-309, 1996
PubMed
15) Burnet PW, Harrison PJ, Goodwin GM et al:Allelic variation in the serotonin 5-HT2C receptor gene and migraine. Neuroreport 8:2651-2653, 1997
PubMed
16) Kusumi M, Adachi Y, Kowa H et al:Serotonin 2C receptor Cys23Ser polymorphism in Japanese patients of chronic headache(Abstract). Cephalalgia 19:330, 1999
 
17) Kowa H, Yasui K, Takeshima T et al:The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet 96:762-764, 2000
PubMed
18) Wessman M, Kallela M, Kaunisto MA et al:A susceptibility locus for migraine with aura, on chromosome 4q24. Am J Hum Genet 70:652-662, 2002
PubMed
19) Awaki E, Takeshima T, Takahashi K:A neuroendocrinological study in female migraineurs:prolactin and thyroid stimulating hormone responses. Cephalalgia 9:187-193, 1989
 
20) Takeshima T, Mishima K, Tabata M et al:Acrophase amplitude of ambulatory blood pressure decreases in migraineurs. Headache 37:577-582, 1997
 
21) Tabata M, Takeshima T, Burioka N et al:Cosinor analysis of heart rate vari-ability in ambulatory migraineurs. Headache 40:457-463, 2000
 
22) Zurak N:Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks. Cephalalgia 17:723-728, 1997
PubMed
23) Weiller C, May A, Limmroth V et al:Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658-660, 1995
PubMed
24) Welch KM, Nagesh V, Aurora SK et al:Periaqueductal gray matter dysfunc-tion in migraine:cause or the burden of illness? Headache 41:629-637, 2001
PubMed
P.99 掲載の参考文献
1) Graham JR, Wolff HG:Mechanism of Migraine Headache and action ergota-mine tartrate. Arc Neurol Psychiatri 39:737-763, 1938
 
2) Sicuteri F, Testi A, Anselmi B:Biochemical investigation in headache:increase in the hydroxyindole accetic acid excretion during migraine attacks. Int Arch Allergy 19:55-58, 1961
 
3) Ferrari MD, Odlink J, Tapparelli C et al:Serotonin metabolism in migraine. Neurology 39:1239-1242, 1989
 
4) Kimball RW, Friedman AP, Vallejo E:Effect of serotonin in migraine patients. Neurology 10:107-111, 1960
PubMed
5) Sicuteri F:Prophylaxic and therapeutic properties of UML-491 in migraine. Int Arch 15:300-307, 1959
 
6) Curran DA, Hinterberger H, Lance JW:Total plasma serotonins 5-hydroxyin-doleacetic acid p-hydroxy-m-methoxymandelic acid excreation in normal and migrainous subject. Brain 88:997-1010, 1965
 
7) Anthony M, Hinterberger H, Lance JW:Plasma serotonin in migraine and stress. Arch Neurol 16:544-552, 1967
PubMed
8) 濱田潤一:片頭痛の病態生理と治療-最近の進歩. 神経治療 18:457-461, 2001
Medical*Online
9) Gotoh F, Komatsumoto S, Araki N et al:Noradrenergic nervous activity in migraine. Arch Neurol 41:951-955, 1984
PubMed
10) Moskowitz MA, Henrikson BM, Beyer B:Trigeminovascular conections and mechanisms of vascular head-ache. In:Handbook of Clinical Neurology 4, ed. by Rose C, Elsevier, Amsterdam, 1986, pp.107-115
 
11) Moskowitz M:Neurogenic versus vascular mechanismof sumatriptan and ergot alkaloids in migraine. Trenals Pharmacol Sci 13:307-311, 1992
 
12) Moskowitz MA, Nozaki K, Kraig RP:Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis trigeminovascular mechanisms. J Neurosci 13:1167-1177, 1993
PubMed
13) Goadsby PJ, Edvinsson L:The trigeminovascular system and migraine studies chracterziing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48-56, 1993
PubMed
14) Goadsby PJ, Hoskin KL:Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5-HT1B/1D receptor a central action in migraine? Ann Neurol 43:711-718, 1998
PubMed
15) 鈴木則宏:セロトニンと片頭痛. Progress in Medicine 21:15-19, 2001
Medical*Online
16) Hoyer D, Clarke DE, Fozard JR et al:Internal Union of Pharmacology classification of receptors for 5-hydroxytryptamine(serotonin). Pharmacol Rev 46:157-203, 1994
 
17) Goadsby PJ:The pharmacology of headache. Neurobiol 62:509-525, 2000
PubMed
18) Goadsby PJ, Hargreaves RJ:Mechanism of action of serotonin 5-HT1B/1D agonists insights into migraine pathophysiology using rizatriptan. Neurology 5(Supppl 2):S8-14, 2000
 
19) Goadsby PJ, Hoskin KL:Inhibition of trigeminal neurons by intravenous administration of the serotonin(5-HT)-1-D receptor agonist zolmitriptan(311C90)are brain stem sites a therapeutic target in migraine? Pain 67:355-359, 1996
 

Part 3 / 片頭痛の診断のポイント

P.111 掲載の参考文献
1) Headache Classification Committee of the International Headache Society:Classification and diagnostic criteria for headache disorders, cranial neuroal-gias and facial pain. Cephalalgia 8(Suppl 7):1, 1988(http://www.i-h-s.org/)
 
2) 坂井文彦:頭痛の分類. 日内会誌 82:3-7, 1993
 
3) 赫彰朗:頭痛の診断と治療. 日内会誌 82:41-49, 1993
 
P.118 掲載の参考文献
1) 岩田誠監修, ADITUS Japan, 2000
 
2) 内潟雅信:頭痛の鑑別診断. JIM 10:107-109, 2000
 
P.129 掲載の参考文献
1) Silberstein SD, Lipton RB, Goadsby PJ et al:Headache in Primary Care, Isis Medical Media Ltd, Oxford, 1999, pp.31-33
 
2) Tian RD, Felsberg GJ, Osumi AK:Herpes virus infection of the CNS;MR findings. AJR 161:167-176, 1993
 
3) 清水俊彦:注意を要する頭痛の鑑別:片頭痛と群発頭痛の最新治療～トリプタン系薬剤を中心に～. 医薬ジャーナル 36:98-105, 2000
 
4) Meyer JS, Kawamura J:cerebral vascular disease and headache. In:The practicing physician's approach to headache, ed by Diamond D, Dalessio DJ, Wil-liams & Wilkins, Baltimore, 1992, pp.162-164
 
5) Thomas EG:Headache associated with intracranial abnormalities. In:Head-ache diagnosis and treatment, ed by Tollison CD, Kunkel RS, Williams & Wilkins, Baltimore, 1993, pp.221-225
 
6) Goodman BW Jr:Tempooral arteritis. Am J Med 67:839-852, 1979
PubMed
7) Donohone CD, Waldman SD, Resor LD:Magnetic resonance imaging in cerebral venous thrombosis, a case report. Headache 27:155-157, 1987
 
8) Bousser MG, Chiras J, Bories J et al:Cerebral venous thrombosis-a review of 38 cases. Stroke 16:199-213, 1985
PubMed
P.136 掲載の参考文献
1) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17 15-22, 1997
PubMed
2) 作田 学:急性頭痛;Geriat Med 33:1087-1089, 1995
 
3) Szasz TS, Hollender A:A contribution to the philosophy of medicine:The basic models of the doctor-patient relationship, A. M. A. Arch Lnt Med 97:583, 1956(米林善男:保健医療の社会学, 有斐閣, 東京, 1983, pp.165-182)
 
4) 江川 寛 編集:医療科学. 医学書院, 東京, 1995, pp.163-183
 
5) 作田 学:頭痛治療の進歩. 内科 87:1499-1503, 2001
 
6) Silberstein SD:Migraine and Pregnancy. Neurol Clin 15:209-231, 1997
PubMed

Part 4 / 片頭痛の治療戦略

P.145 掲載の参考文献
1) Headache Classification Committee of the International Headache Society:Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(suppl 7) 9-96, 1988
 
2) Silberstein SD:Practice parameter:evidence-based guidelines for migraine headache(an evidence-based review):report of the Quality Standards Sub-committee of the American Academy of Neurology. Neurology 55:754-762, 2000
 
3) 日本神経学, 頭痛治療ガイドライン, 2000
 
P.155 掲載の参考文献
1) Skinhoj E:Hemodynamic studies within the brain during migraine. Arch Neu-rol 29:95-98, 1973
 
2) Olesen J, Larsen B, Lauritzen M:Focal hyperemia followed by spreading oli-gemia and impaired activation of rCBF in classic migraine. Ann Neurol 9:344-352, 1981
 
3) Moskowitz MA, Macfarlane R:Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 5:159-177, 1993
PubMed
4) Deleu D, Hanssens Y:Current and emerging second-generation triptans in acute migraine therapy:acomparative review. J Clin Pharmacol 40:687-700, 2000
 
5) Silberstein SD:Practice parameter:evidence-based guidelines for migraine headache(anevidence-based review):report of the Quality Standards Sub-committee of the American Academy of Neurology. Neurology 55:754-762, 2000
 
6) 日本神経学会慢性頭痛治療ガイドライン作成小委員会:慢性頭痛治療ガイドライン2002. 臨床神経 42:330-362, 2002
 
7) Solomon S:Migraine variants. Curr Pain Headache Rep 5:165-169, 2001
PubMed
8) 濱田潤一:Triptanによる片頭痛の治療. 神経内科 54:217-225, 2001
 
9) 寺本 純:片頭痛の治療手引き. 診断と治療社, 東京, 2001
 
10) Headache Classification Committee of the International Headache Society:Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl 7):1-96, 1988
 
11) Ophoff RA, Terwindt GM, Vergouwe MN et al:Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543-552, 1996
PubMed
12) Gutschalk A, Kollmar R, Mohn A et al:Multimodal functional imaging of pro-longed neurological deficits in a patient suffering from familial hemiplegic migraine. Neurosci Lett 332:115-118, 2002
 
13) Evans RW, Linder SL:Management of basilar migraine. Headache 42:383-384, 2002
PubMed
14) Lance JW, Zagami AS:Ophthalmoplegic migraine:a recurrent demyelinating neuropathy? Cephalalgila 21:84-89, 2001
PubMed
15) Milhaud D, Bogousslarsky J, van Melle G et al:Ischemic stroke and active migraine. Neurology 57:1805-1811, 2001
 
16) Linetsky E, Leker RR, Ben-Hur T:Headache characteristics in patients after migrainous stroke. Neurology 57:130-132, 2001
PubMed
17) Yu W, Horowitz SH:Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology 60:120-121, 2003
PubMed
18) Limmroth V, Katsarava Z, Fritsche G et al:Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59:1011-1014, 2002
PubMed
P.167 掲載の参考文献
1) 西間三馨監修, 心身症の診断・治療ガイドライン作成とその実証的研究会作成:心身症の診断・治療ガイドライン. -坪井康次, 端詰勝敬ほか:片頭痛. 協和企画, 東京, 2002, pp.45-64
 
2) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997
PubMed
3) Rasmussen BK:Migraine and tension-type headache in a general popula-tion:Precipitating factors, female hormones, sleep pattern and relation to life-style. Pain 53:65-72, 1993
 
4) Kohler T, Haimerl C:Daily stress as a trigger of migraine attacks:results of thirteen single-subject studies. J Consult Cli Psychol 58:870-872, 1990
 
5) 中井吉英, 阿部哲也:慢性疼痛の心療内科的治療. 医学のあゆみ 203:81-85, 2002
Medical*Online
6) 中井吉英:痛みの治療に用いられる心理学的方法-ペインスコア表を用いたアプローチ. 治療 75:1347-1358, 1993
Medical*Online
7) Mitsikostas DD, Thomas AM:Comobidity of headache and depressive disor-ders. Cephalalgia 19:211-217, 1999
 
8) Lipton RB, Silberstein CB:Why study the comorbidity of migraine? Neurol-ogy 44(suppl):S4-S5, 1994
 
9) Biegon A, Samuel D:Interaction of tricyclic antidepressants with opiate recep-tors. Biochem Phamacol 29:460-462, 1980
 
10) Andrews G, Peters L, Teeson M:The measurement of consumer outcomes in mental health. Australian Health Ministers Advisory Council, Australian Government Publishing Service, Canberra, 1994
 
11) Stahl SM:Independent actions on fear circuits may lead to therapeutic syn-ergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry 63:854-855, 2002
 
12) Ballenger JC, Jonathan RT, Davidson JRT et al:Consensus statement on panic disorder from the international consensus group on depression and anxi-ety. J Clin Psychiatry 59:47-54, 1998
 
13) 田島 治:不安を伴ううつ病と不安障害に対するベンゾジアゼピン(BZD)とSSRIの併用. -その臨床的意義と基礎的メカニズムの再検討-. 分子精神医学 3:130-139, 2003
 

Part 5 / 片頭痛の治療の実際

P.184 掲載の参考文献
1) 坂井文彦, 福内靖男, 松本 清ほか:SN-308(Sumatriptan)皮下注射液の第III相臨床試験-片頭痛患者を対象としたプラセボ注射液との二重盲験試験-. 臨床医薬 16:283-300, 2000
 
2) Perry CM, Markham A:Sumatriptan. An updated review of its use in migraine.Drugs 55:889-922, 1998
PubMed
3) Goadsby PJ, Zagami AS, Donnan GA et al:Oral sumatriptan in acute migraine. Lancet 338:782-783, 1991
PubMed
4) Dixon R, Gillotin C, Gibbens M et al:The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan(311C90)in healthy volunteers. Br J Clin Pharmacol 43:273-281, 1997
PubMed
5) Miranda H, Ortiz G, Figueroa S et al:Depression scores following migraine treatment in patients attending a specialized center for headache and neurology. Headache 41:680-684, 2001
PubMed
6) Tfelt-Hansen P, De Vries P, Saxena PR:Triptans in migraine:a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259-1287, 2000
 
7) Spierings ELH:Management of Migraine. Boston, Butterworth-Heinemann, 1996, pp.95-96
 
8) 寺本 純:片頭痛の治療手引き. 診断と治療社, 東京, 2001, pp.11-19
 
9) The Finnish Sumatriputan Group and the Cardiovascular Clinical Research Group:A Placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 31:332-338, 1991
 
P.194 掲載の参考文献
1) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997
PubMed
2) Headache Classification Committee of the International Headache Society:Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl 7):9-96, 1988
 
3) 頭痛研究会:頭痛, 頭蓋神経痛, 顔面痛の分類及び診断基準. 第18回頭痛研究会会誌 18:91-102, 1991
 
4) 日本神経学会治療ガイドライン慢性頭痛治療ガイドライン作成小委員会(坂井文彦委員長):慢性頭痛治療ガイドライン2002. 臨床神経 42:330-362, 2002
 
P.213 掲載の参考文献
1) Headache Classification Committee of the International Headache Society:Classification and diagnostic criteria for headache disorders, cranial neuralgias and face pain. Cephalalgia 8:12-96, 1988
 
2) Silberstein SD:Practice parameter:Evidence-based guidelines for migraine headache(an evidence-based review):Report of the Quality Standards Sub-committee of the American Academy of Neurology. Neurology 55:754-762, 2000
 
3) 慢性頭痛治療ガイドライン作成小委員会:慢性頭痛治療ガイドライン2002. 臨床神経 42:330-362, 2002
 
4) O'Quinn S, Ephross SA, Williams V et al:Pregnancy and perinatal outcomes in migraineurs using sumatriptan:a prospective study. Arch Gynecol Obstet 263:7-12, 1999
PubMed
5) 平田幸一, 竹島多賀夫:EBMに基づく慢性頭痛の治療. 神経進歩 46:413-430, 2002
 
6) Tfelt-Hansen P:Efficacy and harms of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment:a systemic review based on num-ber needed to treat. Cephalalgia 18:532-538, 1998
 
7) 坂井文彦, 福内靖男, 松本 清ほか:SN-308(Sumatriptan)皮下注射液の第III相臨床試験-片頭痛患者を対象としたプラセボ注射液との二重盲検比較試験. 臨床医薬 16:238-300, 2000
 
8) The Subcutaneous Sumatriptan International Study Group:Treatment of migraine attacks with sumatriptan. N Engl J Med 325:316-321, 1991
 
9) Cull RE, Price WH, Dunbar A:The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. J Neurol Neurosurg Psychia-try 62:490-495, 1997
 
10) Bates D, Ashford E, Dawson R et al:Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology 44:1587-1592, 1994
 
11) The Multinational Oral Sumatriptan and Cafergot Comparative study Group:A randomaized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 31:314-322, 1991
 
12) The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative study Group:A study to compare oral sumatriptan with oral aspirin plus oral meto-clopramide in the acute treatment of migraine. Eur Neurol 32:177-184, 1992
 
13) Tfelt-Hansen P, Henry P, Mulder LJ et al:The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346:923-926, 1995
PubMed
14) Rapoport A, Ramadan N, Adelman J et al:Optimizing the dose of zolmitriptan(Zomig, 311C90)for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology 49:1210-1218, 1997
 
15) Lipton RB, Stewart WF, Stone AM et al:Stratified care vs step care strate-gies for migraine:the Disability in Strategies of Care(DISC)study:a ran-domized trial. JAMA 284:2599-2605, 2000
 
16) Dowson AJ, MacGregor EA, Purdy RA et al:zolmitriptan orally disintegrat-ing tablet is effective in the acute treatment of migraine. Cephalalgia 22:101-106, 2002
 
17) Smith LA, Oldman AD, McQuay HJ et al:Eletriptan for acute migraine(Cochrane Review). In:The Cochrane Library, Issue 3, 2001. Oxford:Update Software. Search date not stated;primary sources:data from all phaseIIIrandomised placebo controlled trials were made available by the manu-facturer, Pfizer Inc. To date, these trials comprise the only data on eletriptan relevant to this review in a published or unpublished from;thus searches of electronic databases for further trials of eletriptan were not conducted.
 
18) Goadsby PJ, Ferrari MD, Olesen J et al:Eletriptan in acute migraine:a dou-ble-blind, placebo-controlled comparison to sumatriptan. Neurology 54:156-163, 2000
 
19) Mathew N, Asgharnejad M, Peykamian M et al:Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology 49:1485-1490, 1997
PubMed
20) Oldman AD, Smith LA, McQuay HJ et al:Rizatriptan for acute migraine(Cochrane Review). In:The Cochrane Library Issue 3, 2001. Oxford:Update Software. Search date July 2000;primary sources Medline, Embase, Cochrane Library, Issue 3,2000, and Oxford Pain Relief Database.
 
21) Dahlof C:Placebo-controlled clinical trials with ergotamine in the acute treat-ment of migraine. Cephalalgia 13:166-171, 1993
 
22) Lipton R:Ergotamine tartrate and dihydroergotamine mesylate:safety pro-files. Headache 37:S33-41, 1997
 
23) Chabriat H, Joire J, Danchot J et al:Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine:multicentre double-blind placebo-controlled study. Cephalalgia 14:297-300, 1994
PubMed
24) Deiner H:Efficacy and safety of intravenous acetylsalicylic acid lysinate com-pared to subcutaneous sumatriptan and parenteral placebo in the acute treat-ment of migraine:a double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 19:581-588, 1999
 
25) Lipton R, Stewart W, Ryan RJ et al:Efficacy and safety of paracetamol, aspi-rin, and caffeine in alleviating migraine headache pain:three double-blind, randomized, placebo-controlled trials. Arch Neurol 55:210-217, 1998
 
26) Massiou H, Serrurier D, Lasserre O et al:Effectiveness of oral diclofenac in the acute treatment of common migraine attacks:a double-blind study ver-sus placebo. Cephalalgia 11:59-63, 1991
 
27) Havanka-Kanniainen H:Treatment of acute migraine attack:ibuprofen and placebo compared. Headache 29:507-509, 1989
PubMed
28) Andersson P, Hinge H, Johansen O et al:Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 9:29-32, 1989
PubMed
29) Myllyla V, Havanka H, Herrala L et al:Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine:comparable effect in a dou-ble-blind, randomized, controlled, parallel-group study. Headache 38:201-207, 1998
 
30) Tek DS, McClellan DS, Olshaker JS et al:A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med 19:1083-1087, 1990
 
31) Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A et al:A double blind study of metoclopramide in the treatment of migraine attacks. J Neurol Neurosurg Psy-chiatry 43:369-371, 1980
 
32) 金 浩澤, 島津邦男, 島津智一ほか:片頭痛発作に対するSO4-Mg静注療法の効果. 日本頭痛学会誌 27:13-15, 2000
 
33) Gotoh F, Tashiro K, Kutsuzawa N et al:Clinical evaluation of KB-2796(lomerizine hydrochloride)on migraine-Late phase II study. Clin Eval 23:13-37, 2001
 
34) Solomon GD, Steel JG, Spaccavento LJ:Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA 250:2500-2502, 1983
 
35) Tfelt-Hansen P, Standnes B, Kangasneimi P et al:Timolol vs propranolol vs placebo in common migraine prophylaxis:a double-blind multicenter trial. Acta Neurol Scand 69:1-8, 1984
PubMed
36) Aube M:Migraine in pregnancy. Neurology 53:S26-28, 1999
PubMed
37) Kaniecki RG:A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 54:1141-1145, 1997
PubMed
38) Gomersall JD, Stuart A:Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychia-try 36:684-690, 1973
 
39) Monro P, Swade C, Coppen A:Mianserin in the prophylaxis of migraine:a double-blind study. Acta Psychiatr Scand Suppl 320:98-103, 1985
 
40) Tomkins GE, Jackson JL, O'Malley PG et al:Treatment of chronic headache with antidepressants:a meta-analysis. Am J Med 111:54-63, 2001
PubMed
41) Martucci N, Manna V, Mattesi P et al:Ergot derivatives in the prophylaxis of migraine:a multicentric study with a timed-release dihydroergotamine formulation. Cephalalgia 3(Suppl 1):151-155, 1983
 
42) Ramadan NM, Silberstein SD, Freitag FG et al:Evidence-based guidelines for migraine headache:pharmacological management for prevention of migraine. Online Pub, 2000
 
43) Schrader H, Stovner LJ, Helde G et al:Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor(lisinopril):randomised, placebo controlled, crossover study. BMJ 322:19-22, 2001
 
44) Schoenen J, Jacquy J, Lenaerts M:Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50:466-470, 1998
PubMed
45) Murphy JJ, Heptinstall S, Mitchell JR:Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 2:189-192, 1988
PubMed
46) Peikert A, Wilimzig C, Kohne-Volland R:Prophylaxis of migraine with oral magnesium:results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16:257-263, 1996
PubMed
47) Sheftell F, Rapoport A, Weeks R et al:Montelukast in the prophylaxis of migraine:a potential role for leukotriene modifiers. Headache 40:158-163, 2000
 
P.222 掲載の参考文献
1) Tfelt-Hansen P:Antiemetic, prokinetic, neuroleptic, and miscellaneous drugs in the acute treatment of migraine. In:The headache, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 1999, pp.445-452
 
2) Pini LA, Bertolotti M, Trenti T et al:Disposition of naproxen after oral administration during and between migraine attach. Headache 33:191-194, 1993
 
3) Volans GN:Absorption of effervescent aspirin migraine Br Med J 4:265-269, 1974
PubMed
4) Tek DS, McClellan DS, Olshaker JS et al:A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine. Ann Emerg Med 19:1083-1087, 1990
 
5) MacGregor EA, Wilkinson M, Bancroft K et al:Domperidone plus paraceta-mol in the treatment of migraine. Cephalalgia 13:124-127, 1993
 
6) McEwen J, O'Connor H, Dinsdale H:Treatment of migraine with intramuscu-lar chlorpromazine. Ann Emerg Med 16:758-763, 1987
 
7) Jones J, Sklar D, Dougherty J et al:Randomized double-blind trial of intrave-nous prochorperazine for the treatment of acute headache. JAMA 261:1174-1176, 1989
 
8) Kayan A, Hood JD:Neuro-otological manifestations of migraine. Brain 107:1123-1142, 1984
PubMed
9) Radtke A, Lempert T Gresty MA et al:Migraine and Meniere's disease. Is there a link? Neurology 59:1700-1704, 2002
 
10) Johnson GD:Medical management of migraine-related dizziness and vertigo. Laryngoscope 108(Suppl 1):1-28, 1988
 
11) Campbell JK, Zagami A:Status migrainosus. In:The headache, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 1999, pp.405-407
 
12) Raskin NH:Treatment of status migrainous:the American experience. Headache 30(Suppl 2):550-553, 1990
 
13) Jomes J, Sklar D, Dougherty J et al:Randomized double-blind trial of intravenous prochlorperazine for treatment of acute headache. JAMA 261:1174-1185, 1989
 
14) McGrath PJ, Holroyd KA, Sorbi MJ:Psychological and behavioral treatment of migraine. In:The headache, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 1999, pp.371-383
 
P.242 掲載の参考文献
1) Headache Classification Committee of the International Headache Society:Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache 8(Suppl 7):1-96, 1988
 
2) Henry GL:Headache. In:Emergency Medicine Vol. II, Mosby-Year Book Inc., St. Louis, 1992, pp.1751-1766
 
3) 間中信也:緊張型頭痛の病態生理と治療. 医学のあゆみ 158:839-841, 1991
Medical*Online
4) Friedman AP, Mikropoulos HE:Cluster headaches. Neurology 8:653-663, 1958
PubMed
5) 手塚博幸:薬物による頭痛. モダンフィジシャン 20:773-776, 2000
 
6) 粟根浩一郎, 上田守三, 横内哲也ほか:慢性硬膜下血腫を合併した特発性頭蓋内圧の1例. 日神経救急研究会誌 12:7-10, 1999
 
7) 太田富雄, 有賀 徹, 石川正恒ほか:頭痛の分類. 脳神経外科, 金芳堂, 京都, 2000, pp.227-246
 
8) Moskowitz MA, Nozaki K, Kraig RP:Neocortical spreading depression pro-vokes the expression of c-fos-protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13:1167-1177, 1993
 
9) 上田守三, 牛久保行男, 都築 隆ほか:Cortical Spreading Depressionはmigraineを惹起するか? 頭痛研究会会誌 24:16-18, 1997
 
10) Lauritzen M:Pathophysiology of the migraine with aura. The spreading depression theory. Brain 117:199-210, 1994
PubMed
11) 鈴木則宏:片頭痛の発生機序と新しい治療. 脳神経 52:287-295, 2000
 
12) Goadsby PJ, Ferrari MD, Olesen J et al:Eletriptan in acute migraine:A double-blind, placebo-controlled comparison to sumatriptan. Neurol 54:156-163, 2000
 
13) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalagia 17:15-22, 1997
 
P.255 掲載の参考文献
1) 濱田潤一:頭痛の発現機序. Modern Physician 20:706-709, 2000
 
2) 濱田潤一:片頭痛の病態仮説. 神経進歩 46:361-375, 2002
 
3) 濱田潤一, 福内靖男:片頭痛の診断と治療. ペインクリニック 21:664-675, 2000
 
4) Saxena PR, Tfelt-Hansen P:Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine. In The Headaches. 2nd ed, ed by Olesen J, Tfelt-Hansen P, Welch KMA, Lippincott Williams & Wilkins, Philadelphia, 2000, pp.411-438
 
5) 濱田潤一, 福内靖男:総論. -頭痛の最新治療とトリプタン系薬剤の位置付け-. 医薬ジャーナル 36:3047-3053, 2000
 
6) Ferrari MD:Migraine. Lancet 351:1043-1051, 1998
PubMed
7) Goadsby PJ:The pharmacology of headache. Prog Neurobiol 62:509-525, 2000
PubMed
8) Goadsby PJ, Lipton RB, Ferrari MD:Migraine-Current understanding and treatment. N Engl J Med 346:257-270, 2002
PubMed
9) 日本神経学会慢性頭痛治療ガイドライン作成小委員会:日本神経学会治療ガイドライン慢性頭痛治療ガイドライン2002. 臨床神経 42:330-362, 2002
 
10) Hamel E:The biology of serotonin receptors:focus on migraine pathophysi-ology and treatment. Can J Neurol Sci 26(Suppl 3):S2-6, 1999
 
11) Tfelt-Hansen P, De Vries P, Saxena PR:Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259-1287, 2000
 
12) Perry C, Markham A:Sumatriptan. An updated review of its use in migraine. Drugs 55:889-922, 1998
PubMed
13) Tfelt-Hansen P:Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment:a systematic review based on number needed to treat. Cephalalgia 18:532-538, 1998
PubMed
14) 坂井文彦, 福内靖男, 松本清ほか:SN-308(Sumatriptan)皮下注射液の第III相臨床試験. -片頭痛患者を対象としたプラセボ注射液との二重盲検比較試験-. 臨床医薬 16:283-300, 2000
 
15) 坂井文彦, 福内靖男, 松本清ほか:SN-308(Sumatriptan)皮下注射液の第III相臨床試験. -群発頭痛患者を対象としたプラセボ注射液との二重盲検比較試験-. 臨床医薬 16:301-323, 2000
 
16) Dahlof C:Sumatriptan nasal spray in the acute treatment of migraine:a review of clinical studies. Cephalalgia 19:769-778, 1999
 
17) Weitzel KW, Thomas ML, Small RE et al:Migraine:a comprehensive review of new treatment options. Pharmacotherapy 19:957-973, 1999
 
18) Deleu D, Hanssens Y:Profiles of 5-HT1B/1D agonists in acute migraine with special reference to second generation agents. Acta Neurol Belg 99:85-95, 1999
PubMed
19) 濱田潤一:Zolmitriptan. 成人病と生活習慣病 32:751-757, 2002
 
20) Ferrari MD, Roon KI, Lipton RB et al:Oral triptans(serotonin 5-HT1B/1D agonists)in acute migraine treatment:a meta-analysis of 53 trials. Lancet 358:1668-1675, 2001
 
21) Spencer CM, Gunasekara NS, Hills C:Zolmitriptan. A review of its use in migraine. Drugs 58:347-374, 1999
PubMed
22) Goadsby PJ, Ferrari MD, Olesen J et al:Eletriptan in acute migraine:a double-blind, placebo-controlled comparison to sumatriptan. Neurology 54:156-163, 2000
 
23) Strijbos PJ, Parsons AA, Fugeli A:Eletriptan Pfizer. Curr Opin Invest Drugs 3:1359-1368, 2002
 
P.268 掲載の参考文献
2) JAPAN DRUGS編集委員会:2002～2003年版, JAPAN DRUGS(日本医薬品総覧), メディカルレビュー社, 東京, 2002, pp.1-1911
 
3) 日本医薬情報センター編:日本医薬品集. 2003(第26版), じほう, 東京, 2002, pp.1-2535
 
P.276 掲載の参考文献
1) Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders cranial neuralgia and facial pain. Cephalalgia 8(Suppl):1-96, 1988
 
2) 久保田紀彦:慢性反復性頭痛やめまいに脳波検査. 日本医事新報 61:157, 1993
 
3) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997
PubMed
4) 根来 清:頭痛の分類と疫学. medicina 39:914-916, 2002
 
5) 平田幸一:慢性頭痛の診断と初期対応. 痛みと臨床 2:9-19, 2002
 
6) 赫 彰郎, 手塚博幸:片頭痛, 群発頭痛. 日内会誌 82:41-49, 1993
 
7) 柴田興一, 岩田 誠:頭痛の診断と治療-30の大学病院による診断と治療シリーズ. 真興交易医書出版部, 東京, 1998, pp.80-93
 
8) 五十嵐久佳, 早川 功:患者の言葉からどのように痛みの性状を理解するか. 治療 78:17-22, 1996
 
9) 高橋 昭:頭痛患者の診かたと鑑別診断. 日内会誌 82:34-40, 1993
 
10) 大生定義:緊急性を要する頭痛の診断・治療. 治療 78:33-38, 1996
 
11) Schaltenbrand G:Neuere Anschuungen Zur Pathophysiologie der Liquor-zirkulation. Zentralbl Neurochir 3:290-300, 1938
 
12) Rando TA, Fishman RA:Spontaneous intracranial hypotension:report of two cases and review of the literature. Neurology 42:481-487, 1992
PubMed
13) Schmidt MH, Binder DK:Spontaneous intracranial hypotension. Contempo-rary Neurosurgery 24:1-4, 2002
 
14) Schievink WI, Wijdicks EFM, Meyer FB et al:Spontaneous intracranial hypotension mimicking aneurysmal subarachnoid hemorrhage. Neurosurgery 48:513-517, 2001
 
15) 木下泰伸, 寺下俊雄, 寺田友昭ほか:激しい頭痛で発症し, 特徴的な神経放射線学的所見を呈したspontaneous intracranial hypotensionの2例. 脳外 25:437-442, 1997
 
16) Spelle L, Boulin A, Tainturier C et al:Neuroimaging features of spontaneous intracranial hypotension. Neuroradiology 43:622-627, 2001
PubMed
17) 生坂政臣:片頭痛, 群発頭痛. 治療 78:53-59, 1996
 
18) 川田純也:頭痛患者の生活指導. medicina 39:966-968, 2002
 
19) 間中信也:鎮痛剤の使い方と薬剤誘発性頭痛. medicina 39:962-965, 2002
 

Part 6 / 片頭痛患者への生活指導と服薬指導

P.287 掲載の参考文献
1) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997
PubMed
2) Van den Bergh V, Amery WK, Waelkens J:Trigger factors in migraine:a study conducted by the Belgian Migraine Society. Headache 27:191-196, 1987
 
3) Rasmussen BK, Olesen J:Migraine with aura and migraine without aura:an epidemiological study. Cephalalgia 12:221-228, 1992
PubMed
4) Russell MB, Rasmussen BK, Fenger K et al:Migraine without aura and migraine with aura are distinct clinical enities:a study of four hundred and eighty-four male and female migraineurs from the general population. Cepha-lalgia 16:239-245, 1996
 
5) Mathew NT:Differential diagnosis in headache-identifying migraine in pri-mary care. Cephalalgia 18(Suppl 22):32-39, 1998
 
6) Zagami AS, Rasmussen BK:Symptomatology of migraine without aura. In:The Headaches(2nd edition), ed. by Olesen J, Tfelt-Hansen P, Welch, KMA, Lippincott Williams & Wilkins, Philadelphia, 2000, pp.337-343
 
7) Spierings ELH, Ranke AH, Honkoop PC:Precipitating and aggravating fac-tors of migraine versus tension-type headache. Headache 41:554-558, 2001
 
8) Martin VT, Behbehani MM:Toward a rational understanding of migraine trig-ger factors. Med Clin North Am 85:911-941, 2001
 
9) Robbins L:Precipitating factors in migraine:a retrospective review of 494 patients. Headache 34:214-216, 1994
 
10) Peatfield RC, Glover V, Littlewood JT et al:The prevalence of diet-induced migraine. Cephalalgia 4:179-183, 1984
PubMed
11) Jarish R, Wantke F:Wine and headache. Int Arch Allergy Immunol 110:7-12, 1996
 
12) Littlewood JT, Gibb C, Glover V et al:Red wine as a cause of migraine. Lancet 1:558-559, 1988
PubMed
13) Selby G, Lance JW:Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiat 23:23-32, 1960
PubMed
14) Rasmussen BK:Migraine and tension-type headache in a general population:precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 53:65-72, 1993
 
15) Vijayan N, Gould S, Watson C:Exposure to sun and precipitation of migraine. Headache 20:42-43, 1980
 
16) Blau JN, Solomon F:Smell and other sensory disturbances in migraine. J Neurol 232:275-276, 1985
 
P.300 掲載の参考文献
1) http://www.headaches.org (National Headache Fundationのホームページ)
 
2) http://ashnet.org (American Headache Societyのホームページ)
 
3) Headache Classification Committee of the International Headache Society:Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalargia 8(suppl 7):1-96, 1988
 
4) Ng YT, Butler IJ:Sphenoid sinusitis masquerading as migraine headaches in children. J Child Neurol 16:882-884, 2001
 
5) Katsarava Z, Lehnerdt G, Duda B et al:Sensitization of trigeminal nocieption specific for migraine but not pain for sinusitis. Neurol 59:1450-1453, 2002
PubMed
6) Silberman SD(the US Headache Consortium):Practical parameter:Evi-dence-based guideline for migraine headache(an evidence-based review). Neurology 55:754-763, 2000
 
7) National Headache Fundation:Therapeutic guide for the treatment of Head-ache. I-VII, 2000
 
8) Goadsby PJ, Lipton RB, Ferrrari MD:Migraine-current understanding and treatment. N Engl J Med 24:257-268, 2002
 
9) Lipton RB, Mazer C, Newman LC et al:Sumatriptan relieves migrainelike headaches associated with carbon monoxide exposure. Headeche 37:392-395, 1997
PubMed
10) Moran JC, Sanchez E, Ulla M et al:Hemicranial headache caused by orbital cellulites auccessfully treated with sumatriptan. An Med Interna 17:282, 2000
 
11) http://www.migraineheip.com (GlaxoSmithKline社のホームページ)
 
12) Bates D, Ashford E, Dawson R et al:Subcutaneous sumatriptan during migraine aura. Sumatriptan Aura Study Group. Neurol 44:1587-1592, 1994
 
13) Tomita M, Suzuki N, Igarashi H et al:Evidence against strong correlation between chest symptome and ischemic coronary changes after subcutaneous sumatriptan injection. Intern Med 41:622-625, 2002
 
14) Ferrari MD, Goadsby PJ, Roon KI et al:Triptans in migraine:detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633-658, 2002
PubMed
15) Sandrini, G, Farkkila M, Burgess G et al:Eleriptan vs sumatriptan. A double blind, placebo-controlled, multiple migraine attack study. Neurol 59:1210-1217, 2002
 
16) Lloyd DK, Pilgrim AJ, Simmons VE:Coronary vasospasm and sumatriptan. BMJ 305:310-311, 1992
PubMed
17) Meschia JF, Malkoff MD, Biller J:Reversible segmental cerebral arterial vasospasm and cerebral infarction:possible association with excessive use of sumatriptan and Midrin. Arch Neurol 55:712-714, 1998
PubMed
18) From Quality Standards Subcomittee of American Acafemy of Neurology:Practical parameter:Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. (Summary statement). Neurology 45:585-587, 1995
 
19) Tfelt-Hansen P, Saxena PR, Dahlof C et al:Ergotamine in the acute treatment of migraine. Brain 123:9-18, 2000
PubMed
20) 清水俊彦:片頭痛-治療-予防的治療. 診断と治療 90:871-876, 2002
 
21) Katsaravava Z, Fritsche G, Muessig M et al:Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurol 57:1694-1698, 2001
 
22) Gaist, D, Hallas J, Sindrup SH et al:Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 50:161-165, 1996
PubMed
23) Snow V, Weiss K, Wall EM et al:Pharmacological management of acute attacks of migraine and prevention of migraine headache. Ann Int Med 137:840-849, 2002
PubMed
24) Silberstein, SD:Migraine:preventive treatment. Curr Med Res Opin 17(Suppl 1):S87-93, 2001
 
25) Hrering R, Kuritzky A:Sodium valproate in the prophylactic treatment of migraine. Cephalalgia 12:81-84, 1992
 
26) Sheftell F, Rapoport A, Weeks R et al:Montelukast in polyphylaxis of migraine:a potential role for leukotiene modifiers. Headache 40:158-163, 2000
 
27) Tronvik E, Stovner LJ, Helde G et al:Prophylactic treatment of migraine with an angiotensin II receptor blocker:a randomized controlled trial. JAMA 289:65-69, 2003
PubMed
P.309 掲載の参考文献
1) 岩田誠:片頭痛治療薬の使い方. 頭痛診療のコツと落とし穴, 坂井文彦編, 中山書店, 東京, 2003, pp.130-131
 
2) 荒木信夫:頭痛治療の新しい展開. Annual Review神経2003, 柳澤信夫ほか編, 中外医学社, 東京, 2003, pp.76-85
 
3) 森松光紀:前兆のある片頭痛. 臨床医のための片頭痛エッセンス, 片山宗一編, ライフサイエンス, 東京, 2000, pp.68-73
 
4) 片山宗一:トリプタンの服用時期について. 頭痛診療のコツと落とし穴, 坂井文彦編, 中山書店, 東京, 2003, pp.160-161
 
5) Headache Classification Committee of International Headache Society:Classi-fication and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl 7):9-96, 1988
 
6) Stark S, Spierings ELH, McNeal S et al:Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 40:513-520, 2000
 
7) Mathew NT, Kailasam J, Gentry P et al:Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan:a comparative open trial. Head-ache 40:464-465, 2000
PubMed
8) Tfelt-Hansen P, Saxena PR, Dahlof CH et al:Ergotamine in the acute treat-ment of migraine. A review and European consensus. Brain 123:9-18, 2000
 
9) 後藤文男, 田代邦雄, 沓沢尚之ほか:KB-2796(塩酸ロメリジン)の片頭痛に対する臨床評価後期第II相臨床試験. 臨床評価 23:13-37, 1995
 
P.318 掲載の参考文献
1) Cady RK, Sheftell F, Lipton RB et al:Economic implications of early treat-ment of migraine with sumatriptan tablets. Clin Ther 23:284-291, 2001
 
2) Olesen J:Cerebral and extracranial circulatory disturbances in migraine:pathophysiological implications. Cerebrovasc Brain Metab Rev 3:1-28, 1991
PubMed
3) Snow V, Weiss K, Wall EM et al:Pharmacologic management of acute attacks of migraine and prevention of migraine headache.Ann Intern Med 137:840-849, 2002
PubMed
4) Silberstein SD, Lipton RB, Breslau N:Migraine:association with personality characteristics and psychopathology. Cephalalgia 15:358-369, 1995
PubMed
5) Sadock BJ, Sadock VA:Kaplan & Sadock Synopsis of Psychiatry. Behavioral Science/Clinical Psychiatry 9th ed. Lippincott Williams & Wilkins, USA, 2003
 
6) Sugahara H:Physiological rationale of aggressive behavior:a brain blood per-fusion hypothesis. Med Hypotheses 57:745-749, 2001
 
7) Moldin SO, Scheftner WA, Rice JP et al:Association between major depres-sive disorder and physical illness. Psychol Med 23:755-761, 1993
 
8) Fava M, Anderson K, Rosenbaum JF:"Anger attacks":possible variants of panic and major depressive disorders. Am J Psychiatry 147:867-870, 1990
PubMed
9) Eng PM, Fitzmaurice G, Kubzansky LD et al:Anger expression and risk of stroke and coronary heart disease among male health professionals. Psycho-som Med 65:100-110, 2003
 
10) Marcus DA:Gender differences in treatment-seeking chronic headache suf-fers. Headache 41:698-703, 2001
 
11) Juang KD, Wang SJ, Fuh JL et al:Comorbidity of depressive and anxiety disor-ders in chronic daily headache and its subtype. Headache 40:818-823, 2000
 
12) Reynolds DJ, Hovanitz CA:Life event stress and headache frequency revis-ited. Headache 40:111-118, 2000
 
13) Mitskostas DD, Thomas AM:Comorbidity of headache and depressive disorders. Cephalalgia 19:211-217, 1999
 
14) Gibar O, Bazak Y, Harel Y:Gender, primary headache, and psychological distress. Headache 38:31-34, 1998
 
15) Ho KH, Ong BK, Lee SC:Headache and self-assessed depression scores in Singapore University undergraduates. Headache 37:26-30, 1997
PubMed
16) Tamminga CA:Diseases of the mind and brain. Am J Psychiatry 159:1826, 2002
 
P.329 掲載の参考文献
1) 五十嵐(淺倉)久佳:頭痛患者への指導の重要性. 日本医事新報 4089:17-22, 2002
Medical*Online
2) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997
PubMed

書評

最近チェックした商品履歴

Loading...